Advertisement
Research ArticleBehavioral Pharmacology
Open Access

Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist

N. Levy-Cooperman, G. McIntyre, L. Bonifacio, M. McDonnell, J. M. Davenport, P. S. Covington, L. S. Dove and E. M. Sellers
Journal of Pharmacology and Experimental Therapeutics December 2016, 359 (3) 471-481; DOI: https://doi.org/10.1124/jpet.116.236547

Article Information

vol. 359 no. 3 471-481
DOI 
https://doi.org/10.1124/jpet.116.236547
PubMed 
27647873
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received July 13, 2016
  • Accepted September 16, 2016
  • Published online November 9, 2016.

Article Versions

Copyright & Usage 
Copyright © 2016 by The Author(s) This is an open access article distributed under the CC BY Attribution 4.0 International license.

Author Information

  1. N. Levy-Cooperman,
  2. G. McIntyre,
  3. L. Bonifacio,
  4. M. McDonnell,
  5. J. M. Davenport,
  6. P. S. Covington,
  7. L. S. Dove, and
  8. E. M. Sellers
  1. Altreos Research Partners, Inc., Toronto, Ontario, Canada (N.L.-C.); IntelliDev Consulting, LLC, Lansdale, Pennsylvania (G.M.); Lodestar Pharma Consulting, LLC, Durham, North Carolina (L.B.); INC Research Toronto, Inc. Early Phase CRO, Toronto, Ontario, Canada (M.M.); Furiex Pharmaceuticals, Inc., an affiliate of Allergan plc, Parsippany, New Jersey (J.M.D., P.S.C., L.S.D.); DL Global Partners Inc. and University of Toronto, Toronto, Ontario, Canada (E.M.S.)
  1. Address correspondence to:
    Dr. Naama Levy-Cooperman, Altreos Research Partners, Inc. 50 Wanda Road, Toronto, Ontario, M6P 1C6, Canada. E-mail: nlevy-cooperman{at}altreos.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: September 2016 to December 2024

AbstractFullPdf
Sep 2016211091
Oct 20161780121
Nov 201662371132
Dec 20163610759
Jan 2017455339
Feb 2017493327
Mar 2017344119
Apr 2017322617
May 2017153615
Jun 2017181817
Jul 2017102012
Aug 2017123327
Sep 201741915
Oct 201762925
Nov 201783313
Dec 2017102612
Jan 2018313811
Feb 201853218
Mar 2018122613
Apr 201842024
May 201872418
Jun 201842524
Jul 201871627
Aug 201821727
Sep 201822449
Oct 201844472
Nov 201823471
Dec 201821569
Jan 201942559
Feb 201943064
Mar 201962977
Apr 201932171
May 2019102667
Jun 201941786
Jul 201951971
Aug 201992269
Sep 201921786
Oct 201912677
Nov 201964272
Dec 201992456
Jan 202082963
Feb 202022649
Mar 202034062
Apr 202022653
May 202051145
Jun 202011644
Jul 202054333
Aug 202015078
Sep 202022047
Oct 202043262
Nov 2020112259
Dec 202061952
Jan 202102149
Feb 202161849
Mar 2021151538
Apr 2021101752
May 2021144146
Jun 202162738
Jul 202134344
Aug 202162050
Sep 202122543
Oct 202121949
Nov 202122042
Dec 202152029
Jan 20223949
Feb 202252345
Mar 202252139
Apr 202293243
May 202252026
Jun 202241327
Jul 202251513
Aug 202241936
Sep 202282140
Oct 202281467
Nov 202231327
Dec 202241620
Jan 202341521
Feb 2023101427
Mar 202331120
Apr 202310615
May 202381034
Jun 202351118
Jul 20232924
Aug 2023101622
Sep 20232912
Oct 20239821
Nov 202331818
Dec 202374512
Jan 20244505
Feb 202431622
Mar 202401721
Apr 2024527326
May 202452211
Jun 202441519
Jul 202441516
Aug 2024101933
Sep 202442415
Oct 202471812
Nov 20247139
Dec 2024161

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleBehavioral Pharmacology

Abuse Potential of Eluxadoline

N. Levy-Cooperman, G. McIntyre, L. Bonifacio, M. McDonnell, J. M. Davenport, P. S. Covington, L. S. Dove and E. M. Sellers
Journal of Pharmacology and Experimental Therapeutics December 1, 2016, 359 (3) 471-481; DOI: https://doi.org/10.1124/jpet.116.236547
Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement